Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) Modulation of neuroinflammati...
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assay...
The proprietary GPC3 targeting peptide is being licensed from RayzeBio pursuant to an existing license agreement. Upon in-license of product candidates by ...
ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ("the Agr...
Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- ...
Addressing a long-term shortcoming in DNA evidence for rape and sexual assault cases, New Orleans-based InnoGenomics has developed a nanotech method, Sperm...
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics company, have launched...
APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency Joenja® is a targeted treat...
GENETWORx is a clinical diagnostics laboratory based outside of Richmond, VA, that specializes in molecular pathogen and pharmacogenomic testing. GEN...
SARS-CoV-2 spike protein (B.1.351 strain) vaccine is the first and only protein-based variant COVID-19 booster vaccine approved in Great Britain and the ...
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge ...
Zeon Corporation (Zeon; head office: Chiyoda-ku, Tokyo; President and CEO: Kimiaki Tanaka), through its subsidiary Zeon Specialty Materials Inc. (Californi...
"Partnering with Immunome represents AbbVie's commitment to developing and commercializing novel treatment approaches for solid tumors," said Steve Davidse...
© 2025 Biopharma Boardroom. All Rights Reserved.
